Fulcrum stock slumps after muscle disorder drug fails in late-stage study

Fulcrum Therapeutics (FULC.O), opens new tab said on Thursday its experimental drug to treat a type of muscle disorder failed to meet the main goal in a late-stage study, sending the company's shares down nearly 70% before the bell.